M 7583 companion diagnostic - HTG Molecular Diagnostics/Merck

Drug Profile

M 7583 companion diagnostic - HTG Molecular Diagnostics/Merck

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HTG Molecular Diagnostics; Merck KGaA
  • Developer HTG Molecular Diagnostics
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research B cell lymphoma

Most Recent Events

  • 03 Apr 2018 HTG Molecular Diagnostics has patent protection for nuclease protection methods for detection of nucleotide variants in Japan
  • 26 Feb 2018 HTG Molecular Diagnostics has patent protection for "Methods of Co-detecting mRNA and Small Non-coding RNA" in Australia
  • 14 Oct 2016 HTG Molecular Digonstics and Merck collaborate to develop M 7583 companion diagnostic for B-cell lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top